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Patients With Systolic Dysfunction
Results From the HF-ACTION (Heart Failure:
A Controlled Trial Investigating Outcomes of Exercise Training) Trial
Objectives This study sought to examine the association between baseline beta-blocker (BB) dose and outcomes in the
HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.
Background Beta-blockers reduce morbidity and mortality in chronic heart failure (HF) patients with reduced ejection fraction,
but it is unclear whether titrating to higher BB doses improves outcomes in this setting.
Methods The HF-ACTION trial was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients with systolic
dysfunction (New York Heart Association functional class II to IV, left ventricular ejection fraction 0.35) ran-
domized to exercise training versus usual care, with median follow-up of 2.5 years. The BB dose at baseline was
standardized with carvedilol equivalents and analyzed as a continuous variable and by discrete dose groups. The
relationship between BB dose and the primary endpoint of all-cause mortality or all-cause hospitalization and
other cardiovascular secondary endpoints was determined before and after adjustment for variables significantly
associated with outcomes in the HF-ACTION cohort.
Results Ninety-five percent of patients were receiving a BB. There was a significant inverse relationship between BB dose and
all-cause death or hospitalization but not other cardiovascular endpoints after adjustment for other predictors of out-
come, with a linear benefit up to the 50-mg daily dose. There was a significant association between BB dose and
change in peak VO2 at 3 months. There was no increase in bradycardia with higher doses of BB.
Conclusions There was a significant inverse relationship between BB dose and the endpoint of all-cause death or all-cause
hospitalization in this well-treated HF cohort with systolic dysfunction, supporting recommendations that titrating
doses up to 50 mg/day might confer a benefit in such patients. (Exercise Training Program to Improve Clinical
Outcomes in Individuals With Congestive Heart Failure; NCT00047437) (J Am Coll Cardiol 2012;60:208–15)
© 2012 by the American College of Cardiology FoundationBeta-blockers (BBs) are an important pharmacological ther-
apy and reduce morbidity/mortality in patients with heart
failure (HF) due to a reduced left ventricular ejection
fraction (LVEF) (1). Guidelines recommend using BB
therapy to treat outpatients with HF at doses consistent
with those studied in randomized, controlled trials. There is
little evidence, however, that clinical trial BB doses are
being used in clinical practice (2). Furthermore, it is unclear
whether there is a dose-response relationship between BBs
and outcomes. In the only study prospectively designed to
test dose-response relationships with the BB carvedilol in
patients with systolic HF, Bristow et al. (3) reported
dose-related improvements in LVEF and survival. How-
ever, this study was limited by a small sample size and a low
number of deaths, making it difficult to interpret the
association with survival. In a post hoc subgroup analysis of
the MERIT-HF (Metoprolol CR/XL Randomized Inter-
vention Trial in congestive Heart Failure) trial, no dose-
response relationship with mortality was observed for meto-
prolol CR/XL in the overall cohort, but a wide variation in
dose-response existed between patients (4). Heart rate
reduction was similar across 3 dose groups, indicating the
degree of beta-blockade might have been equivalent and
thus limiting the ability to test a true association between
dose and mortality benefit, because previous studies havedemonstrated that the degree of heart rate reduction might
be related to outcome (5–7).
The HF-ACTION (Heart Failure: A Controlled Trial
Investigating Outcomes of Exercise Training) trial was the
largest trial to date to test the effects of exercise training versus
usual care in HF patients with moderate-to-severe left ventric-
ular (LV) systolic dysfunction. In the HF-ACTION trial,
approximately 95% of the 2,331 patients received a BB,
providing a large, well-treated contemporary HF population in
which to explore relationships between BB dose and outcomes.
We aimed to examine the relationship between baseline BB
dose and outcomes in the HF-ACTION study population,
hypothesizing that patients taking higher doses might experi-
ence improved outcomes. In addition, we aimed to examine
whether higher doses of BBs were associated with an increase
in bradycardia and a decrease in other adverse cardiovascular
events such as stroke and myocardial infarction (MI).
Methods
The HF-ACTION trial design and outcomes have been
previously described (8,9). Briefly, the study was a multi-
center, randomized, controlled trial testing the long-term
safety and efficacy of aerobic exercise training plus evidence-
based medical therapy versus evidence-based medical ther-
apy alone in medically stable outpatients with LV systolic
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Beta-Blocker Dose and Outcomes From the HF-ACTION Trial July 17, 2012:208–15dysfunction (LVEF 35%) and
New York Heart Association func-
tional class II to IV HF. Adult
patients receiving angiotensin-
converting enzyme inhibitors and/or
angiotensin receptor blockers and
beta-adrenergic blockade for 6
weeks (unless there was a docu-
mented rationale for variation)
were eligible. Investigators were
provided with the followingx in-
structions in the operations man-
ual with regard to use of evidence-
ased BB therapy and dose titration: patients must be receiving
ptimal HF therapy according to American Heart Associa-
ion/American College of Cardiology and Heart Failure Soci-
ty of America guidelines or have documented rationale for
ariation and be receiving stable doses for 6 weeks before
nrollment. There was no specific forced titration strategy
sed, but there was education and reinforcement to achieve
vidence-based levels of target doses on the basis of clinical
rials. The primary endpoint was the composite of all-cause
eath or all-cause hospitalization. Patients were randomly
ssigned to usual care alone or usual care plus exercise training,
onsisting of a prescription of supervised aerobic exercise
raining at 60% to 70% of heart rate reserve 3/week, followed
y home-based training at the same intensity 5/week, total-
ng 36 sessions. Randomization was stratified by center and
F etiology. Participants were followed for a median of 2.5
ears.
ata considerations and outcome measures. Patient
haracteristics, health statuses, laboratory values, and phys-
ological parameters at rest and during a cardiopulmonary
xercise (CPX) test were collected on standardized forms at
Figure 1 Distribution of Doses
Percentage of patients in each dose group (0 dose or no beta-blocker:
5.5%; 1 to 13 mg dose: 21%; 14 to 25 mg dose: 23%; 26 to 50 mg dose:
36%; 51 to 200 mg dose: 14%).
Abbreviations
and Acronyms
BB  beta-blocker
CPX  cardiopulmonary
exercise
HF  heart failure
LV  left ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
VO2  oxygen uptakeaaseline and at several points throughout the study (labo-
atory values only at baseline). Beta-blocker dose at baseline
as standardized with carvedilol equivalents and analyzed as
continuous variable and by discrete dose groups (0, 1 to 13,
4 to 25, 26 to 50, 51 to 200 mg daily). Dosing groups were
elected on the basis of the common titration schedule for
arvedilol (i.e., doubling of the dose every 2 to 4 weeks up
o target doses recommended by guidelines) (1).
The composite primary endpoint of all-cause mortality
nd all-cause hospitalization and an endpoint of mortality
lone were determined and adjusted with variables found to
e significantly associated with outcomes (10). Other pre-
pecified secondary endpoints included cardiovascular mor-
ality or cardiovascular hospitalization, cardiovascular mor-
ality alone, and cardiovascular mortality or HF
ospitalization. Adverse cardiovascular events were col-
ected throughout the study and included fatal or nonfatal
F hospitalization, MI, unstable angina pectoris, arrhyth-
ia, bradycardia, stroke, or transient ischemic attack. Bra-
ycardia was defined as symptomatic bradycardia with a
eart rate 50 beats/min. All events were adjudicated by a
linded clinical events committee. Exercise and functional
arameters of a 6-min walk test, exercise time on a CPX
est, peak oxygen uptake (VO2), and heart rate at peak
xercise were also examined.
tatistical methods. Baseline characteristics were summa-
ized by counts and percentages for categorical variables and
y medians with interquartile ranges for continuous vari-
bles. The unadjusted relationship between BB dose at
aseline and the primary endpoint was explored with
iecewise regression models. The linear and piecewise linear
odels were compared with the null model with likelihood
atio tests. For the primary endpoint (all-cause death or
ospitalization) and secondary endpoint (all-cause death),
redictive models were developed with a broad range of
andidate variables, including demographic data, medical
istory, laboratory values, exercise test values, and quality-
f-life indexes (Kansas City Cardiomyopathy Question-
aire). These models provide a useful tool for estimating the
isk of the given endpoint for specific patients and were used
or adjustment in this analysis. Cox proportional hazards
odeling was used to assess the relationship between
utcomes and BB dose as a continuous variable before and
fter adjustment for the variables found to be significantly
ssociated with each endpoint. A p value 0.05 was
onsidered statistically significant for all analyses. The
elationship between BB dose as a continuous variable and
xercise parameters at 3, 12, and 24 months was analyzed
ith linear regression models that included the exercise
arameters during follow-up as the response variables and
he BB dose along with potential confounders as indepen-
ent variables. Inverse probability weighting was used to
djust for missingness of the exercise parameters during
ollow-up. The exercise variables were transformed to
chieve normality when needed. Statistical analysis was
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July 17, 2012:208–15 Beta-Blocker Dose and Outcomes From the HF-ACTION Trialperformed by the Duke Clinical Research Institute with
SAS software (version 9.2, Cary, North Carolina).
Results
Of the 2,331 patients enrolled in the HF-ACTION trial,
2,325 patients were included in this analysis; 6 patients
with missing information at baseline were excluded. Only
128 (5.5%) patients were not receiving a BB. There was
a broad distribution of doses in this cohort. Excluding
Figure 2 All-Cause Death or Hospitalization by Beta-Blocker Do
Piecewise linear fit statistically significant. All-cause death or hospitalization by be
Dots represent event rate at most common doses on the basis of distribution of d
Baseline Characteristics by BB Use at Randomization (N  2,325)Table 1 Baseline Characteristics by BB Use at Randomization
Characteristics
No BBs
(n  128)
Age, yrs 64
Female, % 27
Black, % (n  2,290) 27
BMI, kg/m2 (n  2,318) 28
NYHA HF functional class, %
II 56
III/IV 44
HF etiology, ischemic, % 56
SBP (n  2,321), mm Hg 114
LVEF (n  2,321), % 23
History of diabetes, % 5
BUN (n  2,022), mg/dl 23
Sinus rhythm (n  2,287), % 76
HR at peak exercise (median) (n  2,323), beats/min 126
CPX duration (n  2,303), min 9.0
6MWT distance (n  2,274), m 351
Peak VO2 (n  2,269), ml/kg/min 14.6
BB beta-blocker; BMI body mass index; BUN blood urea nitrogen; CPX cardiopulmonary ex
raction; NYHA  New York Heart Association; VO2  oxygen uptake; 6MWT  6-min walk test.those patients not receiving BB at randomization, the
median BB dose was 38 mg carvedilol-equivalents daily
(1st quartile  25 mg, 3rd quartile  50 mg). The most
ommon dosing range was 26 to 50 mg daily (36%),
ollowed by 14 to 25 mg daily (23%) (Fig. 1). In total,
3% of patients did not change BB dose groups during
he study, 6% died, and 15% had missing data; therefore,
nly 6% of patients changed dose groups by the last
ssessment.
Baseline
ker dose at baseline, showing a linear relationship up to 50 mg daily dose.
2,325)
BB Dose, mg
p Value
3
90)
14–25
(n  544)
26–50
(n  834)
51–200
(n  329)
60 58 57 0.0001
27 29 24 0.11
30 33 44 —
29 31 33 0.0001
65 65 68 —
35 35 32 —
57 46 46 0.0001
112 112 112 0.07
25 25 24 0.01
21 37 18 0.0006
20 20 19 0.002
81 81 83 0.41
120 118 117 0.0001
.3 9.7 10.0 9.2 0.05
372 375 374 0.37
.0 14.7 14.5 14.3 0.46
SBP systolic blood pressure; HF heart failure; HR heart rate; LVEF left ventricular ejectionse at
ta-bloc
oses.(N 
1–1
(n  4
62
32
30
29
59
41
56
110
24
19
21
79
122
9
366
14
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Beta-Blocker Dose and Outcomes From the HF-ACTION Trial July 17, 2012:208–15Baseline characteristics are shown in Table 1. Patients not
receiving a BB were older and more often white, whereas black
subjects were more often in the highest dose group. There was
no difference in dose distribution on the basis of sex. Those not
receiving a BB more often had a higher blood urea nitrogen
level. Patients in the highest BB dose group had a higher body
mass index and were younger. There was no difference between
the dose groups in baseline exercise parameters. There was a
significant reduction in maximal heart rate at peak exercise with
increasing doses, indicating the degree of beta-blockade was
indeed greater in the higher dose groups.
The relationship between all-cause death/hospitalization
and dose is shown in Figure 2, and the clinical outcomes are
shown in Table 2. The median follow-up was 2.5 years. A
iecewise linear fit was used to model the relationship
etween the BB dose and the primary endpoint. When
ompared with a linear relationship, the piecewise linear
odel provided a better fit (likelihood ratio statistic  25.8,
p  0.0001). The same relationship was used for all-cause
eath. After adjusting for the variables found to be signif-
Outcomes and BB Dose at RandomizationTable 2 Outcomes and BB Dose at Randomization
Chi-Square p Value
HR (95% CI)
(for 10 U Increase
in BB Dose*)
All-cause death or all-cause
hospitalization
(1,430 events, 67%)
Unadjusted 26.11 0.0001 0.93 (0.91–0.96)
Adjusted† 5.43 0.02 0.96 (0.93–0.99)
All-cause death
(307 events, 15%)
Unadjusted 8.27 0.004 0.92 (0.88–0.98)
Adjusted‡ 0.86 0.35 0.97 (0.92–1.03)
*Hazard ratios (HRs) are applicable for doses up to 50 mg/day. For dose50 mg/day, HR 1.00.
†Adjusting by Kansas City Cardiomyopathy Questionnaire symptom stability, left ventricular ejection frac-
tion, region, sex, ventricular conduction,Weber class, blood urea nitrogen, andmitral regurgitation. ‡Adjust-
ing by sex, body mass index, loop diuretics, Canadian Cardiovascular Society angina class, creatinine,
exercise duration, ventricular conduction, and left ventricular ejection fraction.
BB  beta-blocker; CI  confidence interval.
Cardiovascular Adverse Events by BB Use at RaTable 3 Cardiovascular Adverse Events by B
Event Type, %
No BBs
(n  128)
1–13
(n  490)
Cardiovascular 45 43
HF 34 32
Myocardial infarction 4 3
Unstable angina 7 7
Arrhythmia 18 16
Bradycardia 3 2
Stroke 2 2
Cardiovascular events, n
0 56 57
1 13 16
2 12 10
3 or more 20 17BB  beta-blocker; HF  heart failure.cantly associated with the primary endpoint of all-cause
eath or hospitalization, higher BB dose remained significantly
ssociated with a lower rate of the primary endpoint (hazard
atio: 0.96; p 0.02). Although there was a significant inverse
elationship between BB dose and all-cause death alone in a
nivariate model (p  0.004), it became nonsignificant after
djusting for confounding variables (p  0.65). This relation-
hip remained significant when adjusted for sex, body mass
ndex, loop diuretic dose, serum creatinine, and Canadian
ardiovascular Society angina class and became nonsignificant
fter adjustment for CPX testing duration. Although each of
he other cardiovascular endpoints showed a similar significant
nverse relationship with BB dose in a univariate model, these
lso became nonsignificant when adjusted for other clinical
ariables (data not shown).
The relationship between BB dose and exercise parame-
ers (change in CPX duration, 6-min walk test, and peak
O2 at 3, 12, and 24 months) was not significant when
adjusted for baseline clinical variables, except for change in
peak VO2 at 3 months. Those in the highest BB dose group
ad the greatest increase in peak VO2 at 3 months (3.9%;
p  0.048), but the relationship between these variables
was not significant at 12 or 24 months. No relationship
was observed between changes in CPX duration or 6-min
walk distance and the dose of BB at 3, 12, or 24 months.
The relationships between BB dose and cardiovascular
adverse events are shown in Table 3. Patients who were
not receiving a BB had the highest number of cardiovas-
cular events, and those in the 26-to-50-mg daily dose
group seemed to have the lowest cardiovascular adverse
event rate. There was no increase in the incidence of
bradycardia with increasing doses of BB.
Discussion
There were several important findings from this study. First,
there was a significant relationship between BB dose and
the adjusted risk for the primary outcome of all-cause death
izatione at Randomization
Dose, mg
p Value
14–25
n  544)
26–50
(n  834)
51–200
(n  329)
41 33 43 0.0001
29 22 30 0.0001
5 4 3 0.59
10 6 7 0.15
13 13 14 0.56
1 2 1 0.35
3 2 5 0.09
0.004
59 68 57
18 13 19
8 7 9
16 13 15ndomB Us
BB
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July 17, 2012:208–15 Beta-Blocker Dose and Outcomes From the HF-ACTION Trialor hospitalization; however, no significant relationship be-
tween BB dose and secondary outcomes was observed after
adjustment for other clinical variables. Second, there was a
significant relationship between BB dose and change in peak
VO2 at 3 months but not for other exercise or functional
parameters. In addition, our study showed no increased inci-
dence of bradycardia on higher doses of BB in this cohort;
rather there were more cardiovascular and HF events in
patients not receiving a BB compared with those receiving
moderate-to-high doses even after adjustment for other key
prognostic variables. Finally, approximately 50% of patients
were not receiving target doses of BBs.
The relationship between higher doses of BB and an
improvement in the adjusted risk for the primary composite
endpoint of all-cause death or hospitalization seemed to be
linear up to the highest dose group. Although guidelines
recommend moderate-to-high doses of BB therapy, many
patients are not titrated to doses demonstrated to be advanta-
geous in large, multisite, randomized, controlled clinical trials,
and registries (11). Data from the OPTIMIZE-HF (Orga-
nized Program to Initiate Lifesaving Treatment in Hospi-
talized Patients With Heart Failure) registry showed that, in
patients hospitalized for HF, the mean daily dose of BBs
before hospital admission was one-half the recommended
target dose, and most patients were not titrated to target
doses up to 90 days after discharge. In fact, at 60 and 90
days after discharge, only 17.5% and 7.9% of patients were
receiving target doses of carvedilol and metoprolol, respec-
tively (11). In part, this reluctance toward titration to
evidence-based doses might be based on lack of definitive
evidence that there is a dose-response relationship between
BB therapy and clinical outcomes, health system barriers
that prevent easy titration of the medications to target doses,
and a concern about an increase in adverse events—
particularly in those who are older and have significant
comorbidities (12–14).
Recently, the CIBIS-ELD (Cardiac Insufficiency Biso-
prolol Study in Elderly) study evaluated the tolerability of
bisoprolol and carvedilol in elderly patients; only 31% of
patients were able to reach target doses (15). However,
other studies have shown good BB tolerability in this
patient population (16). The findings of the CIBIS-ELD
study were more likely due to an aggressive titration
schedule; this supports the titration scheme of the European
Society of Cardiology guidelines, which allows for a slower
titration to achieve dose targets (17).
The evidence for a dose-response relationship for cardio-
vascular drugs has been limited. Two studies have shown a
benefit between higher doses of angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers and
clinical outcome (18,19); these showed an advantage on a
composite endpoint of HF hospitalization and death but
not on death alone. Very little evidence exists with regard
to BB dose and outcomes in HF patients. The REVERT
(REversal of VEntricular Remodeling with Toprol-XL)
trial examined the effects of BB therapy on LV remodelingin asymptomatic patients and showed that the benefits on
LV end-systolic volume index and LVEF were dose-
dependent (20). As previously mentioned, the MOCHA
(Multicenter Oral Carvedilol Heart failure Assessment)
study demonstrated a positive dose-response relationship
between BB dose and LVEF improvement as well as an
improvement in survival (3). However, given that this was a
study of only 300 patients with only 30 deaths, the findings
with regard to survival are difficult to interpret. A meta-
analysis of BB dose and clinical outcome in HF patients
found no significant relationship between all-cause mortal-
ity and BB dose (21); however, there were important
limitations, as with any meta-analysis. In our study, all-
cause mortality did not show a dose-related benefit with BB
therapy when adjusted for other clinical variables, in partic-
ular when CPX duration was added to the model. This
finding is not surprising, given that the strongest baseline
predictor of both the primary and mortality endpoints in the
HF-ACTION predictive model was exercise duration on
CPX (10). Yet the primary endpoint of all-cause death/
hospitalization remained significant even after adjustment
for CPX duration, indicating this relationship was uniquely
important in this cohort. There remains no definitive
evidence of a dose-response relationship between BB ther-
apy and outcomes in a randomized, controlled trial. In the
absence of randomized testing, that an association exists
might indicate the effect could be more or less pronounced
than our results demonstrate.
The clinical improvement found with higher doses was
consistent with the improvement in peak VO2 at 3 months
ith higher doses of beta-blockade. This finding is note-
orthy, because phase II studies of BB therapy have failed
o demonstrate improvement in maximal exercise tolerance,
eak VO2, or 6-min walk with BB therapy versus placebo
but have shown favorable trends on submaximal exercise
(22–24). Certainly one of the concerns about BB therapy is
potential impairment in exercise performance at higher BB
doses. Our finding that there is no attenuation of exercise
performance with higher doses of BBs should allow clini-
cians to feel more comfortable with BB titration, particu-
larly in those patients who have important reductions in
baseline exercise capacity, as seen in the HF-ACTION
study. Furthermore, our study showed no increased inci-
dence of bradycardia with higher BB doses, supporting the
concept that patients might receive more benefit than harm
with moderate-to-higher doses. This is particularly reassur-
ing if adverse events are a concern preventing dose titration.
We found approximately one-half of the patients were not
at target doses. These findings suggest that there is consid-
erable room for BB up-titration in clinical practice.
Interestingly, there seemed to be racial differences in the
baseline dose of BB therapy. Black patients were more often
receiving a higher baseline dose of BB than white patients or
other races. It is unclear whether this finding was related to
the need to have relatively higher doses of BB therapy to
achieve similar efficacy. There was no statistical interaction
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Beta-Blocker Dose and Outcomes From the HF-ACTION Trial July 17, 2012:208–15between race and BB dose. This is an interesting finding
that requires further analysis to better understand the
differences between BB dosing and outcomes in black
patients.
Study limitations. Our findings should be interpreted in
the context of several potentially important limitations.
First, this is a post hoc analysis. Although this study
population is broad, patients who were not ambulatory and
patients with preserved systolic function were excluded.
This might have limited the number of elderly patients
enrolled and conferred a generally younger population with
an average age of 58 years, compared with the BB clinical
trials in which the average age was roughly 62 years. By
contrast, this study includes a relatively large cohort of
women and black patients. Second, the use of dose conver-
sions is an imperfect method for comparing doses. In this
cohort, the median patient weight was 90 kg (1st quartile 
76 kg, 3rd quartile  106 kg). Guideline dosing recommen-
ations suggest that target carvedilol doses for patients75 kg
s 100 mg/day, relative to 200 mg/day for metoprolol. This
ould convert to a 2:1 dosing ratio with metoprolol.
owever, doses used in HF clinical trials might suggest a
:1 conversion ratio. We therefore conducted a sensitivity
nalysis with both methods; there was no difference in heart
ate reduction throughout the distribution of doses with a
:1 conversion compared with the 2:1 conversion formula.
here was also no difference in the clinical endpoint results.
inally, an important potential confounder is that sicker
atients might be less able to tolerate higher BB doses.
lthough we adjusted for numerous known predictors of
dverse outcome, the possibility of important unidentified
rognostic indicators must be considered. A true dose-
esponse relationship should be assessed in a randomized
linical trial.
onclusions
igher BB dose in ambulatory HF patients with reduced
jection fraction was associated with a significantly lower
ate of all-cause death or all-cause hospitalization, even after
djustment for important prognostic covariates. Higher
oses were not associated with increased incidence of
radycardia, with the best cardiovascular event profile in
atients at target doses. These data support the current
linical guideline recommendations that BB therapy should
e titrated to moderate-to-high doses as used in random-
zed, controlled clinical trials.
Acknowledgments
The authors wish to thank Drs. Kerry Lee, Stephen Ellis,
and Karen Chiswell for their thoughtful suggestions and
statistical consultation and Morgan deBlecourt for her
editorial assistance with the manuscript.Reprint requests and correspondence: Dr. Mona Fiuzat, Duke
University Medical Center, Cardiology, DUMC Box 3356, Dur-
ham, North Carolina 27710. E-mail: mona.fiuzat@duke.edu.
REFERENCES
1. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 compre-
hensive heart failure practice guideline. J Card Fail 2010;16:e1–194.
2. O’Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade
M. Demographics, clinical characteristics, and outcomes of patients
hospitalized for decompensated heart failure: observations from the
IMPACT-HF registry. J Card Fail 2005;11:200–5.
3. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces
dose-related improvements in left ventricular function and survival in
subjects with chronic heart failure. MOCHA Investigators. Circula-
tion 1996;94:2807–16.
4. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol
CR/XL and clinical outcomes in patients with heart failure: analysis of
the Experience in Metoprolol CR/XL Randomized Intervention Trial
in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2002;40:
491–8.
5. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm
relationships with bisoprolol benefit in chronic heart failure in CIBIS
II Trial. Circulation 2001;103:1428–33.
6. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate,
blood pressure, and beta-blocker dose on outcome and the differences
in outcome between carvedilol and metoprolol tartrate in patients with
chronic heart failure: Results from the COMET trial. Eur Heart J
2005;26:2259–68.
7. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate
should one aim for when treating patients with heart failure with a
beta-blocker? Experiences from the Metoprolol Controlled Release/
Extended Release Randomized Intervention Trial in Chronic Heart
Failure (MERIT-HF). J Am Coll Cardiol 2005;45:252–9.
8. Whellan DJ, O’Connor CM, Lee KL, et al. Heart Failure and a
Controlled Trial Investigating Outcomes of Exercise Training (HF-
ACTION): design and rationale. Am Heart J 2007;153:201–11.
9. O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of
exercise training in patients with chronic heart failure: HF-ACTION
randomized controlled trial. JAMA 2009;301:1439–50.
10. O’Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to
morbidity and mortality in patients with chronic heart failure with
systolic dysfunction: the HF-ACTION predictive risk score model.
Circ Heart Fail 2011;5:63–71.
11. Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-
blocker therapy before, during, and after hospitalization for heart
failure (from Organized Program to Initiate Lifesaving Treatment in
Hospitalized Patients with Heart Failure). Am J Cardiol 2008;102:
1524–9.
12. Yancy CW, Fonarow GC, Albert NM, et al. Influence of patient age
and sex on delivery of guideline-recommended heart failure care in the
outpatient cardiology practice setting: findings from IMPROVE HF.
Am Heart J 2009;157:754–62.e2.
13. Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA,
Heidenreich PA. Potential impact of optimal implementation of
evidence-based heart failure therapies on mortality. Am Heart J
2011;161:1024–30.e3.
14. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the
outpatient cardiology practice setting: findings from IMPROVE HF.
Circ Heart Fail 2008;1:98–106.
15. Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of
bisoprolol vs. carvedilol in elderly patients with heart failure: the
CIBIS-ELD trial. Eur J Heart Fail 2011;13:670–80.
16. Krum H, Hill J, Fruhwald F, et al. Tolerability of beta-blockers in
elderly patients with chronic heart failure: the COLA II study. Eur
J Heart Fail 2006;8:302–7.
17. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008:
the Task Force for the Diagnosis and Treatment of Acute and Chronic
Heart Failure 2008 of the European Society of Cardiology. Developed
in collaboration with the Heart Failure Association of the ESC (HFA)
11
2
2
2
2
2
215JACC Vol. 60, No. 3, 2012 Fiuzat et al.
July 17, 2012:208–15 Beta-Blocker Dose and Outcomes From the HF-ACTION Trialand endorsed by the European Society of Intensive Care Medicine
(ESICM). Eur Heart J 2008;29:2388–442.
8. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative
effects of low and high doses of the angiotensin-converting enzyme
inhibitor, lisinopril, on morbidity and mortality in chronic heart
failure. Atlas study group. Circulation 1999;100:2312–8.
9. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose
versus low-dose losartan on clinical outcomes in patients with heart
failure (HEAAL study): a randomised, double-blind trial. Lancet
2009;374:1840–8.
0. Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left
ventricular remodeling in patients with asymptomatic systolic dysfunc-
tion: the REversal of VEntricular Remodeling with Toprol-XL
(REVERT) trial. Circulation 2007;116:49–56.
1. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong
PW. Meta-analysis: beta-blocker dose, heart rate reduction, and2. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and
long-term carvedilol administration on rest and exercise hemodynamic
variables, exercise capacity and clinical conditions in patients with
idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:
1678–87.
3. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML.
Usefulness of bucindolol in congestive heart failure. Am J Cardiol
1990;66:603–7.
4. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind,
placebo-controlled study of the long-term efficacy of carvedilol in
patients with severe chronic heart failure. Circulation 1995;92:
1499–506.
Key Words: beta-blockers y dose y exercise y heart failure y mortality.
APPENDIXdeath in patients with heart failure. Ann Intern Med 2009;150:
784 –94. For a supplementary table, please see the online version of this article.
Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
